Meganathan Kannan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5318719/publications.pdf

Version: 2024-02-01

72	1,072	361045	476904
papers	citations	20 h-index	29 g-index

74	74	74	1264
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	1.9	64
2	Differential profiling of human red blood cells during storage for 52 selected microRNAs. Transfusion, 2010, 50, 1581-1588.	0.8	62
3	Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings. Blood Reviews, 2019, 37, 100583.	2.8	59
4	Membrane arrayâ€"based differential profiling of platelets during storage for 52 miRNAs associated with apoptosis. Transfusion, 2009, 49, 1443-1450.	0.8	56
5	Gene conversions are a common cause of von Willebrand disease. British Journal of Haematology, 2005, 130, 752-758.	1.2	52
6	Disseminated Intravascular Coagulation in Acute Leukemia at Presentation and During Induction Therapy. Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 292-298.	0.7	48
7	Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia. Journal of Thrombosis and Haemostasis, 2009, 7, 1878-1885.	1.9	42
8	Glanzmann's Thrombasthenia: An Overview. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 152-165.	0.7	38
9	Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. American Journal of Clinical Pathology, 2004, 121, 844-7.	0.4	32
10	Roles of protein C, protein S, and antithrombin III in acute leukemia. American Journal of Hematology, 2006, 81, 171-174.	2.0	29
11	Characterisation of mutations and molecular studies of type 2 von Willebrand disease. Thrombosis and Haemostasis, 2013, 109, 39-46.	1.8	28
12	SARSâ€CoVâ€2 infection induces soluble platelet activation markers and PAIâ€1 in the early moderate stage of COVIDâ€19. International Journal of Laboratory Hematology, 2022, 44, 712-721.	0.7	28
13	Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. Cells, 2018, 7, 165.	1.8	27
14	Inherited platelet function disorders versus other inherited bleeding disorders: An Indian overview. Thrombosis Research, 2008, 121, 835-841.	0.8	25
15	Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. Cytokine and Growth Factor Reviews, 2022, 63, 58-68.	3.2	25
16	Hypercoagulable State in Five Thalassemia Intermedia Patients. Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 422-427.	0.7	23
17	Identification of 32 novel mutations in the factor VIII gene in Indian patients with hemophilia A. Haematologica, 2005, 90, 283-4.	1.7	23
18	Mutation reports: Intron 1 and 22 inversions in Indian haemophilics. Annals of Hematology, 2003, 82, 546-547.	0.8	21

#	Article	IF	Citations
19	Factor V Leidenâ€"the commonest molecular defect in arterial and venous thrombophilia in India. Thrombosis Research, 2003, 110, 19-21.	0.8	21
20	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. Thrombosis and Haemostasis, 2021, 121, 992-1007.	1.8	21
21	Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A?. Thrombosis Research, 2003, 109, 71-72.	0.8	20
22	Type I Glanzmann thrombasthenia: Most common subtypes in North Indians. American Journal of Hematology, 2003, 74, 139-141.	2.0	19
23	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	1.9	19
24	Clinico-Hematologic Profile of Factor XIII-Deficient Patients. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 475-480.	0.7	18
25	Increased Prevalence of Antiheparin Platelet Factor 4 Antibodies in Patients May Be Due to Contaminated Heparin. Clinical and Applied Thrombosis/Hemostasis, 2009, 15, 145-151.	0.7	18
26	SARS-CoV-2 infection- induced growth factors play differential roles in COVID-19 pathogenesis. Life Sciences, 2022, 304, 120703.	2.0	18
27	Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. Thrombosis and Haemostasis, 2013, 109, 652-660.	1.8	17
28	Protein C system defects in Indian children with thrombosis. Annals of Hematology, 2005, 84, 85-88.	0.8	15
29	Carrier Detection in Glanzmann Thrombasthenia. American Journal of Clinical Pathology, 2008, 130, 93-98.	0.4	15
30	Lipocalin-2, S100A8/A9, and cystatin C: Potential predictive biomarkers of cardiovascular complications in COVID-19. Experimental Biology and Medicine, 2022, 247, 1205-1213.	1.1	14
31	Increase of Plasma TNF-Î± Is Associated with Decreased Levels of Blood Platelets in Clinical Dengue Infection. Viral Immunology, 2020, 33, 54-60.	0.6	13
32	Congenital vitamin K-dependent coagulation factor deficiency: a case report. Blood Coagulation and Fibrinolysis, 2005, 16, 525-527.	0.5	11
33	Glanzmann's thrombasthenia in North Indians: Sub classification and carrier detection by flow cytometry. Platelets, 2009, 20, 12-15.	1.1	11
34	Prenatal diagnosis of haemophilia A by chorionic villus sampling and cordocentesis: All India Institute of Medical Science experience. Vox Sanguinis, 2007, 92, 79-84.	0.7	10
35	Modulation of clinical phenotype of Glanzmann's thrombasthenia by thrombogenic mutations. Clinica Chimica Acta, 2009, 403, 156-158.	0.5	10
36	Omic Approaches to Quality Biomarkers for Stored Platelets: Are We There Yet?. Transfusion Medicine Reviews, 2010, 24, 211-217.	0.9	9

#	Article	IF	Citations
37	Enhanced In Vitro Wound Healing Using PVA/B-PEI Nanofiber Mats: A Promising Wound Therapeutic Agent against ESKAPE and Opportunistic Pathogens. ACS Applied Bio Materials, 2021, 4, 8466-8476.	2.3	9
38	Impact of 789Ala/Ala genotype on quantitative type of von Willebrand disease. Annals of Hematology, 2009, 88, 479-483.	0.8	8
39	TFPI and FXIII negatively and S100A8/A9 and Cystatin C positively correlate with D-dimer in COVID-19. Experimental Biology and Medicine, 2022, 247, 1570-1576.	1.1	8
40	Carrier detection in severe von Willebrand?s disease. Annals of Hematology, 2004, 83, 625-7.	0.8	7
41	First report of a FVII-deficient Indian patient carrying double heterozygous mutations in the FVII gene. Thrombosis Research, 2005, 115, 535-536.	0.8	6
42	Acquired von Willebrand's disease associated with gastrointestinal angiodysplasia: a case report. Haemophilia, 2006, 12, 452-455.	1.0	6
43	Impact of Thrombogenic Mutations on Clinical Phenotypes of von Willebrand Disease. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 281-287.	0.7	6
44	An Update on the Prevalence and Characterization of H-PF4 Antibodies in Asian-Indian Patients. Seminars in Thrombosis and Hemostasis, 2009, 35, 337-343.	1.5	5
45	Acquired Glanzmannâ€™s thrombasthenia associated with Hairy cell leukaemia. European Journal of Clinical Investigation, 2009, 39, 1110-1111.	1.7	5
46	No genetic abnormalities identified in Î±2<scp>II</scp>b and Î²3: phenotype overcomes genotype in Glanzmann thrombasthenia. International Journal of Laboratory Hematology, 2017, 39, e41-e44.	0.7	5
47	Functional characterization of antibodies against heparinâ€“platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers. Blood Coagulation and Fibrinolysis, 2005, 16, 487-490.	0.5	4
48	Characterization of <scp>VWF</scp> gene conversions causing von Willebrand disease. British Journal of Haematology, 2019, 184, 817-825.	1.2	4
49	Pro CR Global: An effective screening test for thrombophilia. American Journal of Hematology, 2003, 74, 208-210.	2.0	3
50	Laboratory Diagnosis of Heparin-Induced Thrombocytopenia in Asian Indians as Investigated With Functional and Immunologic Methods. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 51-54.	0.7	3
51	Laboratory studies in coagulation disorders. Indian Journal of Pediatrics, 2007, 74, 649-655.	0.3	3
52	Role of RFLP using TspRI for carrier detection in Glanzmannâ€™s thrombasthenia: a report on two families. International Journal of Laboratory Hematology, 2010, 32, e158-e162.	0.7	3
53	Association of VEGF and p53 Polymorphisms and Spiral Artery Remodeling in Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2021, , .	1.8	3
54	Hemophilia A: Role of FVIIIC/vWF Ag in Assisting Linkage Analysis for Carrier Detection. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 127-131.	0.7	2

#	Article	IF	Citations
55	Platelet factor 3 availability test: an effective screening test for types 1 and 2 von Willebrand disease. Annals of Hematology, 2004, 83, 489-490.	0.8	2
56	Clinicohematologic Spectrum in Patientswith Lupus Anticoagulant. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 191-195.	0.7	2
57	Î²2 Glycoprotein 1 in Indian Patients with SLE. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 223-226.	0.7	2
58	Gene tracking in a family of novel identical twins affected by severe type-III von Willebrand Disease (vWD). Thrombosis Research, 2007, 120, 459-462.	0.8	2
59	Coinheritance of Severe von Willebrand Disease With Glanzmann Thrombasthenia. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 529-532.	0.7	2
60	Use of CSGE, TspRI- RFLP and Western Blot in Carrier Detection in an Indian Family with Type I Glanzmann Thrombasthenia.. Blood, 2006, 108, 3975-3975.	0.6	2
61	Therapy-related acute promyelocytic leukemia after treatment of carcinoma breast--a case report. Indian Journal of Pathology and Microbiology, 2006, 49, 251-4.	0.1	2
62	Use of Intron 1 and 22 inversions and linkage analysis in carrier detection of hemophilia A in Indians. Clinica Chimica Acta, 2006, 365, 109-112.	0.5	1
63	Apoptotic Microrna Profiling of Packed Red Blood Cells During Storage.. Blood, 2009, 114, 3145-3145.	0.6	1
64	Gel card in the diagnosis of autoimmune haemolytic anemia. Indian Journal of Pathology and Microbiology, 2005, 48, 322-4.	0.1	1
65	Neonatal thrombosis in India: a report of 14 cases. Thrombosis Research, 2003, 111, 191-192.	0.8	0
66	Identification of 22 novel mutations in patients with Glanzmann's thrombasthenia. Nature Precedings, 2008, , .	0.1	0
67	Study of Prothrombotic Gene Variations Associated with the Risk of Development of Thrombosis in Patients with Down Syndrome. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 507-508.	0.3	0
68	Mutation Screening of GPIIb and GPIIIa Exons by Conformation Sensitive Gel Electrophoresis.. Blood, 2007, 110, 3218-3218.	0.6	0
69	Studies on Platelet Storage Biomarkers: Effect of Different Protein Extraction Buffers on Platelet Gelsolin and B-Actin Profiling. Blood, 2008, 112, 4075-4075.	0.6	0
70	Potential Use of miRNAs as Platelet Biomarkers of Storage.. Blood, 2008, 112, 1991-1991.	0.6	0
71	Glanzmannâ€™s Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). Blood, 2008, 112, 1236-1236.	0.6	0
72	Higher Prevalence of Heparin-Induced Thrombocytopenia Antibodies in Asian Indian Population: Is This Due to Contaminated Heparin?. Blood, 2009, 114, 4182-4182.	0.6	0